- Home
- PLRX vs ATRO Comparison
PLRX vs ATRO Comparison
Compare PLRX & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- ATRO
- Stock Information
- Founded
- PLRX 2015
- ATRO 1968
- Country
- PLRX United States
- ATRO United States
- Employees
- PLRX N/A
- ATRO N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- PLRX Health Care
- ATRO Industrials
- Exchange
- PLRX Nasdaq
- ATRO Nasdaq
- Market Cap
- PLRX 77.3M
- ATRO 844.1M
- IPO Year
- PLRX 2020
- ATRO N/A
- Fundamental
- Price
- PLRX $1.39
- ATRO $35.29
- Analyst Decision
- PLRX Hold
- ATRO Strong Buy
- Analyst Count
- PLRX 10
- ATRO 1
- Target Price
- PLRX $9.79
- ATRO $49.00
- AVG Volume (30 Days)
- PLRX 1.7M
- ATRO 740.4K
- Earning Date
- PLRX 08-06-2025
- ATRO 07-31-2025
- Dividend Yield
- PLRX N/A
- ATRO N/A
- EPS Growth
- PLRX N/A
- ATRO N/A
- EPS
- PLRX N/A
- ATRO N/A
- Revenue
- PLRX N/A
- ATRO $816,288,000.00
- Revenue This Year
- PLRX N/A
- ATRO $8.33
- Revenue Next Year
- PLRX N/A
- ATRO $5.89
- P/E Ratio
- PLRX N/A
- ATRO N/A
- Revenue Growth
- PLRX N/A
- ATRO 13.73
- 52 Week Low
- PLRX $1.10
- ATRO $14.13
- 52 Week High
- PLRX $16.10
- ATRO $37.32
- Technical
- Relative Strength Index (RSI)
- PLRX 53.02
- ATRO 62.79
- Support Level
- PLRX $1.13
- ATRO $29.91
- Resistance Level
- PLRX $1.50
- ATRO $36.48
- Average True Range (ATR)
- PLRX 0.11
- ATRO 1.57
- MACD
- PLRX 0.03
- ATRO 0.12
- Stochastic Oscillator
- PLRX 71.23
- ATRO 73.08
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.